{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:24Z","timestamp":1771824444852,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.cld.2009.05.006","type":"journal-article","created":{"date-parts":[[2009,7,22]],"date-time":"2009-07-22T09:19:43Z","timestamp":1248254383000},"page":"419-427","source":"Crossref","is-referenced-by-count":10,"title":["Ribavirin Analogs"],"prefix":"10.1016","volume":"13","author":[{"given":"William W.","family":"Shields","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Pockros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2009.05.006_bib1","author":"The Department of Health and Human Services Center for Disease Control and Prevention"},{"issue":"5 Suppl. 1","key":"10.1016\/j.cld.2009.05.006_bib2","first-page":"S3","article-title":"Consensus Development Conference Statement: management of hepatitis C","volume":"36","author":"National Institutes of Health","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2009.05.006_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2893.2001.00271.x","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in na\u00efve patients: 1999 update","volume":"8","author":"Thevenot","year":"2001","journal-title":"J Viral Hepat"},{"issue":"3 Suppl. 1","key":"10.1016\/j.cld.2009.05.006_bib4","doi-asserted-by":"crossref","first-page":"83S","DOI":"10.1002\/hep.510260715","article-title":"Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials","volume":"26","author":"Carithers","year":"1997","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2009.05.006_bib5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-123-12-199512150-00001","article-title":"Ribavirin as therapy of chronic hepatitis C: a randomized, double-blind, placebo-controlled trial","volume":"123","author":"Di Bisceglie","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cld.2009.05.006_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","article-title":"Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C","volume":"351","author":"Reichard","year":"1998","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.cld.2009.05.006_bib7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2009.05.006_bib8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.cld.2009.05.006_bib9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2009.05.006_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2006.10.008","article-title":"Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a\/ribavirin treatment","volume":"5","author":"Reddy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2009.05.006_bib11","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","article-title":"Design, synthesis, and broad spectrum antiviral activity of 1-\u03b2-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide and related nucleosides","volume":"15","author":"Witkowski","year":"1972","journal-title":"J Med Chem"},{"key":"10.1016\/j.cld.2009.05.006_bib12","unstructured":"Copegus (ribavirin, USP) [package insert]. Roche Laboratories Inc, Nutley, New Jersey. 2004."},{"issue":"6","key":"10.1016\/j.cld.2009.05.006_bib13","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1128\/AAC.49.6.2164-2171.2005","article-title":"Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: implications for ribavirin metabolism in erythrocytes","volume":"49","author":"Wu","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.cld.2009.05.006_bib14","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1053\/jhep.2002.32672","article-title":"Mechanism of action of ribavirin in the combination treatment of chronic HCV infection","volume":"35","author":"Lau","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2009.05.006_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/AAC.47.1.426-431.2003","article-title":"Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions","volume":"47","author":"Wu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2009.05.006_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1440-1746.2003.03329.x","article-title":"Ribavirin upregulates interleukin-12 receptor and induces T-cell differentiation towards type 1 in chronic hepatitis C","volume":"19","author":"Shiina","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2009.05.006_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(99)80093-2","article-title":"Ribavirin polarizes human T cell responses towards a type 1 cytokine profile","volume":"30","author":"Tam","year":"1999","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2009.05.006_bib18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.cld.2009.05.006_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1542-3565(04)00064-3","article-title":"Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia","volume":"2","author":"Homma","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2009.05.006_bib20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidation damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2009.05.006_bib21","first-page":"194","article-title":"Advances in hepatology research","volume":"8","author":"Pockros","year":"2008","journal-title":"Rev Gastroenterol Disord"},{"issue":"Suppl","key":"10.1016\/j.cld.2009.05.006_bib22","first-page":"418A","article-title":"Telaprevir in combination with peginterferon alfa-2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE 2 study","volume":"48","author":"Zeuzem","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2009.05.006_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","article-title":"R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.cld.2009.05.006_bib24","first-page":"1027A","article-title":"HCV SPRINT-1: bocepravir plus peginterferon alfa-2b\/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients","volume":"48","author":"Kwo","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2009.05.006_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/095632020301400304","article-title":"Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals","volume":"14","author":"Lin","year":"2003","journal-title":"Antivir Chem Chemother"},{"issue":"10","key":"10.1016\/j.cld.2009.05.006_bib26","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.48.10.4006-4008.2004","article-title":"Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin","volume":"48","author":"Wu","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.cld.2009.05.006_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0091270004262974","article-title":"Pharmacokinetics and safety of viramidine, a prodrug of ribavirin in healthy volunteers","volume":"44","author":"Lin","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.cld.2009.05.006_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jhep.2007.02.018","article-title":"Virological response and safety outcomes in therapy-na\u00efve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized phase 2 study","volume":"47","author":"Gish","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2009.05.006_bib29","doi-asserted-by":"crossref","first-page":"273A","DOI":"10.1016\/S0168-8278(06)80739-7","article-title":"The safety and efficacy of viramidine plus PegIFN alfa-2b versus ribavirin plus PegIFN alfa-2b in therapy-na\u00efve patients infected with hepatitis C virus: phase 3 results (VISER 1)","volume":"44","author":"Behamou","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2009.05.006_bib30","doi-asserted-by":"crossref","first-page":"7A","DOI":"10.1016\/S0168-8278(07)61608-0","article-title":"The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy-na\u00efve patients infected with hepatitis C virus: phase 3 results","volume":"46","author":"Marcellin","year":"2007","journal-title":"J Hepatol"},{"issue":"Suppl","key":"10.1016\/j.cld.2009.05.006_bib31","first-page":"1138A","article-title":"Taribavirin exposure analysis from a previous phase 3 trial correlates with phase 2B weight-based dosing interim results","volume":"48","author":"Pockros","year":"2008","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.cld.2009.05.006_bib32","first-page":"433A","article-title":"Treatment week 24 results of weight-based taribavirin versus weight-based ribavirin both with peginterferon alfa-2b in na\u00efve chronic hepatitis C, genotype 1 patients","volume":"48","author":"Lawitz","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2009.05.006_bib34","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1128\/AAC.44.5.1276-1283.2000","article-title":"The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels","volume":"44","author":"Tam","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cld.2009.05.006_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/dkg046","article-title":"Absorption, pharmacokinetics and excretion of levovirin in rats, dogs, and cynomolgus monkeys","volume":"51","author":"Lin","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cld.2009.05.006_bib36","first-page":"H17","article-title":"Combination of levovirin and pegylated interferon \u03b1-2a fails to generate an induction response comparable to ribavirin and pegylated interferon \u03b1-2a in patients with CHC","volume":"9","author":"Pockros","year":"2004","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.cld.2009.05.006_bib37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","article-title":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon","volume":"44","author":"Markland","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.cld.2009.05.006_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/135965350501000503","article-title":"A randomized, double-blind, placebo-controlled dose escalation trial of merimepodib (VX-497) and interferon alpha in previous untreated patients with chronic hepatitis C","volume":"10","author":"McHutchison","year":"2005","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.cld.2009.05.006_bib39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jhep.2007.03.028","article-title":"Phase 2 study of the combination of merimepodib with peginterferon alpha-2b and ribavirin in nonresponders to previous therapy for chronic hepatitis C","volume":"47","author":"Marcellin","year":"2007","journal-title":"J Hepatol"},{"issue":"4 Suppl 1","key":"10.1016\/j.cld.2009.05.006_bib40","first-page":"615A","article-title":"Effect of IMPDH inhibition, Merimepobid (MMPD), assessed in combination with ribavirin (RBV), and alone, on HCV replication: implications regarding RBV's mechanism of action","volume":"44","author":"Hezode","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2009.05.006_bib41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0168-8278(02)00300-8","article-title":"Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon nonresponder patients with chronic hepatitis C","volume":"37","author":"Cornberg","year":"2002","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2009.05.006_bib42","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2006.08.027","article-title":"Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporine A and interferon alpha","volume":"131","author":"Henry","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2009.05.006_bib43","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1177\/096120330501400114","article-title":"Mycophenolate mofetil in patients with hepatitis C virus infection","volume":"14","author":"Ramos-Casals","year":"2005","journal-title":"Lupus"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326109000324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326109000324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T03:03:32Z","timestamp":1685070212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326109000324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1089326109000324"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2009.05.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}